The Conversation (0)
New responsibilities recognize Mr. Sardano's significant accomplishments in securing CPT ® codes for office-based SRT and the growing commercial opportunity the Company now faces
Sensus Healthcare, Inc. (Nasdaq: SRTS) , a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that President Michael Sardano has been appointed to the additional role of Chief Commercial Officer. In this newly created position, Mr. Sardano will direct the company's global sales, marketing and commercial strategy across its portfolio of SRT technologies, Sentinel ® software and related service models.
These expanded responsibilities follow a recent reimbursement milestone from the Centers for Medicare & Medicaid Services (CMS), which established current procedural terminology (CPT) codes specific to the use of superficial radiotherapy (SRT and IG-SRT) for non-melanoma skin cancer. This development has driven heightened interest and demand across dermatology and oncology practices. In his new role, Mr. Sardano will lead efforts to expand physician adoption of SRT, support recurring-revenue models and drive growth across U.S. and international markets.
"We believe we will see a notable uptick in interest for our technology, largely due to a more favorable reimbursement environment for our SRT product," said Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare. "Michael has been at the forefront of securing these wins, while supporting commercial execution around this reimbursement milestone and the future ramp in demand. His strong leadership of our sales and marketing team, combined with our deep customer relationships and best-in-class SRT outcomes over 16 years, powerfully position us to capitalize on this next phase of growth with a heightened focus on commercial strategies."
"I've devoted my career to advocating the clinical and economic benefits of SRT, and I couldn't be more excited about the latest momentum building around our technology," said Michael Sardano. "With dedicated, clear, and favorable reimbursement now in place and an exciting new path for accelerated growth, we are redoubling our focus on expanding access to SRT nationwide and internationally so that more physicians and patients can benefit from this non-invasive, life-changing treatment. I look forward to working more closely with our outstanding commercial team to continue growing the company and advancing our mission."
Michael Sardano joined Sensus Healthcare in 2010 to help start the company and joined full-time in 2013 as Corporate Counsel for Regulatory Affairs, and subsequently held leadership positions including Vice President & General Counsel and then President since 2022. He is a member of the Florida State Bar Association and holds a J.D. from New England Law and a B.S. in Management and Finance from Bentley University.
About Sensus Healthcare
Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com .
Forward-Looking Statements
This press release includes statements that are, or may be deemed, ''forward-looking statements.'' In some cases, these statements can be identified by the use of forward-looking terminology such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately," "potential" or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.
Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release, as a result of the following factors, among others: the possibility that inflationary pressures continue to impact our sales; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; the development by others of new products, treatments, or technologies that render our technology partially or wholly obsolete; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation, or other aspects of our business; the performance of the Company's information technology systems and its ability to maintain data security; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.
Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our "Introductory Note Regarding Forward-Looking Information" and the factors described in the "Risk Factors" section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251114450761/en/
Alliance Advisors IR
Tirth T. Patel
tpatel@allianceadvisors.com
212-201-6614
